ELOX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 22:03):

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases...

Stats
Dzisiejszy wolumen	4 397.00
Średni wolumen	8 289.00
Kapitalizacja rynkowa	2.69M
EPS	$0 ( 2024-04-01 )
Następna data zysków	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-24	Walts Alan Edmund	Buy	7 500	Restricted Stock Units
2024-01-24	Rubin Steven D	Buy	7 500	Restricted Stock Units
2024-01-24	Androski Lindsay	Buy	7 500	Restricted Stock Units
2024-01-24	Aggarwal Sumit	Buy	60 000	Restricted Stock Units
2023-01-30	Walts Alan Edmund	Buy	2 859	Stock Options (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 28 846 630 \| Sell: 836 099

Eloxx Pharmaceuticals Inc Korelacja

10 Najbardziej pozytywne korelacje
PAIC	0.954
SVAC	0.941
MTSL	0.873
CASI	0.869
TLGT	0.866
AGMH	0.861
BLKB	0.857
SVOK	0.855
KC	0.851
ACACU	0.849

10 Najbardziej negatywne korelacje
NETE	-0.961
MMAC	-0.934
RAVN	-0.907
AMRB	-0.891
BOCH	-0.89
SHSP	-0.867
SRAC	-0.837
RMRM	-0.834
LWAC	-0.819
DFFN	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eloxx Pharmaceuticals Inc Finanse

Annual	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-16.65

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-16.65

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1 526.00

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1 378.77

Financial Reports:

No articles found.

Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.